The Every Company
Makes animal-free egg proteins (OvoPro, OvoBoost) via precision fermentation.
On the record
Checkpoint: Delaware patent ruling on US 12,096,784 vs Onego Bio, and confirmation of the 2026 profitable unit economics claim
The call
EVERY has products, customers, and scale-up partners in place, but its core patent is being contested by Onego Bio and its 2026 profitability claim is still unconfirmed.
The Every Company grows egg protein in labs instead of raising chickens, then sells it to food brands. Two things make this hard to replace: they have actual products selling in Walmart and Target, and they own a U.S. patent on their main technology. However, a competitor called Onego Bio is suing them over that same patent in court, and The Every Company promised it would be profitable in 2026, but nobody outside the company has confirmed that actually happened yet. If the court rules against them or if 2026 profits don't materialize as claimed, the whole business becomes much shakier.
Why
01
AI pressure: None apparent. AI does not directly threaten fermented protein sales, though rivals may use AI protein design to speed up strain development. Could AI do the core job? Unlikely.
02
Bigger players: Onego Bio. Onego Bio has its own FDA-cleared ovalbumin product live in market and is suing EVERY over the core US patent. Could a giant copy it? Probably.
03
What protects it. FDA GRAS clearance plus real retail placement at Walmart and Target and manufacturing deals with ADM and Huvepharma give it working supply and sales that Onego Bio must still match.
What would change this call
Delaware court rules on patent 12,096,784 in EVERY vs. Onego Bio case. Determines whether EVERY's core IP moat holds or collapses.
EVERY publicly confirms or fails to confirm profitable unit economics by end of 2026 or Q1 2027. Tests whether the company's central 2026 claim was accurate.
ADM's Clinton, Iowa facility comes online on schedule in 2027. Shows whether manufacturing scale-up via partners is executing as planned.
EVERY publicly confirms or fails to confirm profitable unit economics by end of 2026 or Q1 2027. Tests whether the company's central 2026 claim was accurate.
ADM's Clinton, Iowa facility comes online on schedule in 2027. Shows whether manufacturing scale-up via partners is executing as planned.
Key numbers
- $55M Series D closed, led by McWin Capital
- Huvepharma deal to quadruple OvoPro capacity
- ADM Clinton, Iowa plant to lift output 5x by H2 2027
Named risks
- Core US patent 12,096,784 under active, unresolved Delaware litigation from Onego Bio.
- October 2025 'profitable unit economics in 2026' claim remains unverified by any independent source as of mid-2026.
- ADM Clinton, Iowa facility not operational until 2027, delaying promised fivefold volume increase.
- Demand tailwind tied to avian-flu-driven egg price volatility may fade if conventional egg supply stabilizes.
- Precision-fermentation peers like Perfect Day have historically failed to reach cost parity with commodity animal protein.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Onego Bio | contesting | Delaware patent suit over US 12,096,784 unresolved as of May 2026; both FDA-cleared |
| Perfect Day | gaining on | Perfect Day sold consumer brands to focus on B2B in 2023 amid cost-parity struggles |
| Motif FoodWorks | contesting | Adjacent precision-fermentation peer targeting functional proteins for food manufacturers |
Questions people ask
- Is The Every Company profitable in 2026?
- Not confirmed. In an October 28, 2025 interview, EVERY's leadership said it expected 'profitable unit economics' in 2026, but as of mid-2026 no audited or independently verified confirmation of that milestone has been published, making it the single most-watched unresolved claim about the company.
- Who owns The Every Company?
- The Every Company is private and venture-backed. Investors include Grupo Bimbo (2019), AB InBev's ZX Ventures (2021), Anne Hathaway (2023), and Agronomics Limited (LSE: ANIC), which had invested about £5.9 million by November 2025. Its Series D, closed November 4, 2025, was led by McWin Capital Partners.
- Is The Every Company being sued over its patents?
- Yes. Rival Onego Bio sued EVERY over its US patent (No. 12,096,784) for recombinant ovalbumin. A Wisconsin case was dismissed for lack of jurisdiction on May 5, 2026, but a parallel Delaware case continues, with EVERY seeking sanctions against Onego Bio around May 11, 2026.
- Could AI replace The Every Company?
- Unlikely. EVERY's value comes from strain engineering, fermentation science, and FDA GRAS regulatory clearances for its OvoPro and OvoBoost egg proteins, not knowledge-work software. As of mid-2026 no evidence suggests generative AI threatens its biomanufacturing or distribution business model directly.
- Who is The Every Company's biggest competitor?
- Onego Bio, a Finland-based spinout of VTT, is EVERY's closest rival: it also makes fermentation-based ovalbumin and is one of only two companies with US regulatory clearance for precision-fermented egg protein, and it is actively litigating EVERY's core patent in Delaware as of 2026.
- How much funding has The Every Company raised?
- EVERY closed a $55 million Series D on November 4, 2025, led by McWin Capital Partners, with participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, and SOSV, funding a planned nationwide US retail rollout.
Timeline
- 2026-07-13ADM partnership announced to produce OvoPro at Clinton, Iowa facility opening 2027
- 2026-06-15Huvepharma/Biovet deal announced to quadruple OvoPro production capacity
- 2026-05-11EVERY files motion for sanctions against Onego Bio in patent fight
- 2026-05-05Wisconsin patent lawsuit vs Onego Bio dismissed; Delaware case continues
- 2026-04EVERY appoints its first Chief Revenue Officer for US mass-market push
- 2025-11-04Series D closed: $55M raised, led by McWin Capital Partners
- 2025-10-28CEO states EVERY expects 'profitable unit economics' in 2026
- 2021Clara Foods rebrands as The Every Company (EVERY)
- 2015Company founded as Clara Foods via SOSV's IndieBio accelerator
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- The EVERY Company (Wikipedia)
- EVERY Raises $55 Million in Fresh Capital (2026-01-28)
- Valuation, Funding Rounds & Stock Price (2025-11-03)
- EVERY raise US$55 million in fresh capital, Company Announcement (2025-11-09)
- 'Next year, we will have profitable unit economics' (2025-10-28)
- ADM, EVERY Company Partner to Deliver US-Based Commercial Scale Production of OvoPro Egg White Protein (2026-07-13)
- Judge Dismisses Onego Bio's Lawsuit Against The Every Company in Wisconsin (2026-05-07)
- EVERY and Huvepharma Announce 4x Production Capacity Expansion (2026-06-15)
- ADM partners with The Every Company for precision-fermented egg protein scale up in US (2026-07-15)
- Onego Bio Inc. v. Clara Foods Co. (2026-02-26)
- Judge tosses Onego Bio lawsuit vs EVERY Co in Wisconsin (2026-05-06)
- Alt protein IP war heats up as EVERY seeks sanctions v Onego Bio (2026-05-11)